Mark A. Demitrack
2021
In 2021, Mark A. Demitrack earned a total compensation of $908.3K as SVP and Chief Medical Officer at Trevena, a 42% decrease compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $156,366 |
---|---|
Salary | $473,333 |
Stock Awards | $267,033 |
Other | $11,600 |
Total | $908,332 |
Demitrack received $473.3K in salary, accounting for 52% of the total pay in 2021.
Demitrack also received $156.4K in non-equity incentive plan, $267K in stock awards and $11.6K in other compensation.
Rankings
In 2021, Mark A. Demitrack's compensation ranked 9,093rd out of 12,415 executives tracked by ExecPay. In other words, Demitrack earned more than 26.8% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 9,093 out of 12,415 | 27th |
Division Manufacturing | 4,037 out of 5,508 | 27th |
Major group Chemicals And Allied Products | 1,777 out of 2,378 | 25th |
Industry group Drugs | 1,579 out of 2,099 | 25th |
Industry Pharmaceutical Preparations | 1,175 out of 1,549 | 24th |
Source: SEC filing on May 9, 2022.
Demitrack's colleagues
We found two more compensation records of executives who worked with Mark A. Demitrack at Trevena in 2021.